152152-09-5

Usage

Uses

Used in Pharmaceutical Industry:
2,6-Difluorocinnamic acid is used as a building block for the preparation of various pharmaceuticals due to its unique chemical properties and potential medicinal applications. Its potential anticancer properties make it a valuable compound in the development of new drugs for cancer treatment.
Used in Agrochemical Industry:
2,6-DIFLUOROCINNAMIC ACID is also utilized in the synthesis of agrochemicals, contributing to the development of new pesticides and other agricultural chemicals that can improve crop yields and protect plants from diseases and pests.
Used in Organic Synthesis:
2,6-Difluorocinnamic acid is used as a key intermediate in the synthesis of other fluorinated organic compounds, which have a wide range of applications in various industries, including pharmaceuticals, materials science, and chemical research.
Used in Display Technology:
2,6-Difluorocinnamic acid has been studied for its potential use in liquid crystal displays, where its unique properties could contribute to the development of advanced display technologies with improved performance and energy efficiency.
Used in Optoelectronics:
As a substrate in organic light-emitting diodes, 2,6-Difluorocinnamic acid plays a role in the advancement of optoelectronic devices, which have applications in lighting, displays, and other areas of technology that require efficient light emission.

InChI:InChI=1/C9H6F2O2/c10-7-2-1-3-8(11)6(7)4-5-9(12)13/h1-5H,(H,12,13)/p-1/b5-4+

Upstream product

• 141-82-2 malonic acid 
• 437-81-0 2,6-difluorobenzaldehyde 

Downstream Products

• 1352428-64-8 C₃₀H₃₄F₂N₄O₂ 
• 1261024-88-7 C₉H₈F₂O 
• 207226-37-7 1,3-difluoro-2-vinyl-benzene 

Relevant academic research and scientific papers

Multifunctional novel Diallyl disulfide (DADS) derivatives with β-amyloid-reducing, cholinergic, antioxidant and metal chelating properties for the treatment of Alzheimer's disease

A series of novel Diallyl disulfide (DADS) derivatives were designed, synthesized and evaluated as chemical agents, which target and modulate multiple facets of Alzheimer's disease (AD). The results showed that the target compounds 5a-l and 7e-m exhibited significant anti-Aβ aggregation activity, considerable acetylcholinesterase (AChE) inhibition, high selectivity towards AChE over butyrylcholinesterase (BuChE), potential antioxidant and metal chelating activities. Specifically, compounds 7k and 7l exhibited highest potency towards self-induced Aβ aggregation (74% and 71.4%, 25 μM) and metal chelating ability. Furthermore, compounds 7k and 7l disaggregated Aβ fibrils generated by Cu2+-induced Aβ aggregation by 80.9% and 78.5%, later confirmed by transmission electron microscope (TEM) analysis. Besides, 7k and 7l had the strongest AChE inhibitory activity with IC50 values of 0.056 μM and 0.121 μM, respectively. Furthermore, molecular modelling studies showed that these compounds were capable of binding simultaneously to catalytic active site (CAS) and peripheral anionic site (PAS) of AChE. All the target compounds displayed moderate to excellent antioxidant activity with ORAC-FL values in the range 0.546-5.86 Trolox equivalents. In addition, absorption, distribution, metabolism and excretion (ADME) profile and toxicity prediction (TOPKAT) of best compounds 7k and 7l revealed that they have drug like properties and possess very low toxic effects. Collectively, the results strongly support our assertion that these compounds could provide good templates for developing new multifunctional agents for AD treatment.

Synthesis of Z-N-alkenylformamides

Commercially available difluorinated benzaldehyde was converted to the Z-N-alkenylformamides via Horner-Emmons olefination and Curtius rearrangement, followed by reduction with tri-tert-butoxy-aluminohydride. Copyright Taylor & Francis Group, LLC.